Long-term burden, trends, and inequality of lower respiratory infections attributable to Mycoplasma pneumoniae among children and adolescents in low- and middle-income countries, 1990–2023: a Global Burden of Disease Study 2023 analysis Authors: Yuqi Zhang, Lei Zhang, Li Zhang, Yufen Huang Published: 2026 ABSTRACT AbstractBackgroundMycoplasma pneumoniae (M. pneumoniae) is an under-recognised contributor to paediatric lower respiratory infection (LRI) burden in low- and middle-income countries (LMICs), where progress in child survival remains uneven and pneumonia control continues to be shaped by international child-health targets, including the Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). This study aimed to quantify the fatal and non-fatal burden of LRIs attributable to M. pneumoniae among individuals aged 0–19 years in LMICs from 1990 to 2023.MethodsUsing estimates from the Global Burden of Disease (GBD) Study 2023 for 93 LMICs, we extracted deaths, disability-adjusted life years (DALYs), and corresponding rates for LRIs attributable to M. pneumoniae, using GBD population estimates as denominators. Analyses were stratified by age, sex, socio-demographic index (SDI), and geographic region. Temporal trends were assessed using joinpoint regression and summarised by average annual percentage changes. Inequality, decomposition, and frontier analyses were conducted to evaluate socioeconomic gradients, drivers of change, and performance gaps.ResultsIn 2023, M. pneumoniae accounted for an estimated 24,019 deaths and 2,098,712 DALYs among children and adolescents in LMICs. The burden was heavily concentrated in low-SDI regions, with mortality and DALY rates approximately three to four times higher than those in middle-SDI regions. Western Sub-Saharan Africa had the highest regional burden. Infants (<1 year) accounted for the highest proportion of severe outcomes, with notable sex-based variations across SDI groups. From 1990 to 2023, mortality and DALY rates declined significantly, but the pace of improvement slowed around 2010–2016 in several settings. In low-SDI regions, population growth contributed +110,933 DALYs and age-structure change contributed approximately +60,144 DALYs, whereas epidemiological improvement contributed −117,946 DALYs, yielding a net increase of about +53,131 DALYs. Frontier analysis identified substantial health-system efficiency gaps, particularly in Sub-Saharan Africa.ConclusionsM. pneumoniae is a major and inequitably distributed contributor to the LRI burden among children and adolescents in LMICs, with the highest risk in infancy and in low-resource settings. The 2023 estimates should be interpreted in the context of the emerging post-pandemic resurgence. Accelerated progress will require earlier diagnosis, stronger community-to-facility pneumonia care pathways, and regionally adapted antimicrobial stewardship.Keywords: Mycoplasma pneumoniae (M. pneumoniae), lower respiratory infections (LRIs), children and adolescents, low- and middle-income countries (LMICs), Global Burden of Disease (GBD) Highlight box Key findings • In 2023, Mycoplasma pneumoniae (M. pneumoniae) caused a substantial fatal and non-fatal lower respiratory infection (LRI) burden among children and adolescents in low- and middle-income countries (LMICs), with the highest burden in low-socio-demographic index (SDI) settings and in infants. Mortality and disability-adjusted life year (DALY) rates declined from 1990 to 2023, but progress slowed in several settings after 2010, and demographic growth offset epidemiological gains in low-SDI regions. Frontier analysis showed substantial performance gaps in several high-burden countries, whereas some low-resource settings performed close to the theoretical best level for their SDI. What is known and what is new? • Previous studies mainly focused on aggregate LRI burden or on selected pathogens, with limited pathogen-specific, long-term, and LMIC-focused estimates for M. pneumoniae. • This study provides a Global Burden of Disease 2023-based assessment of deaths, DALYs, temporal trends, inequality, decomposition, and frontier performance for Mycoplasma-attributable LRIs among people aged 0–19 years in LMICs from 1990 to 2023. What is the implication, and what should change now? • Prevention and control strategies should prioritize infancy, low-SDI settings, and Sub-Saharan Africa, while strengthening diagnostic access, community-to-facility case-management pathways, and antimicrobial stewardship. • The 2023 endpoint should be interpreted cautiously because it likely precedes the full post-pandemic resurgence observed in 2024–2025. Introduction Lower respiratory infections (LRIs) remain a leading cause of paediatric morbidity and mortality worldwide, with a disproportionately high burden borne by children and adolescents in low- and middle-income countries (LMICs) (1). This inequitable distribution remains highly relevant to current child-survival agendas, including the Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD), which identified accelerated reduction of preventable childhood pneumonia mortality as a global priority (2). Mycoplasma pneumoniae (M. pneumoniae) is a prevalent atypical bacterial pathogen implicated in a substantial proportion of community-acquired pneumonia and other LRIs within paediatric populations, particularly in school-aged children and adolescents (3). Despite its clinical significance, comprehensive and comparable estimates of the specific disease burden attributable to Mycoplasma—spanning both mortality and disability—remain scarce across most LMIC settings. This gap persists because pathogen-specific assessment is constrained by limited access to molecular diagnostics, frequent reliance on syndromic or clinical diagnosis without aetiological confirmation, and fragmented surveillance systems (4,5). Previous global burden estimates and epidemiological reviews have largely focused on the overall LRI burden or on selected major pathogens such as Streptococcus pneumoniae, influenza virus, and respiratory syncytial virus (RSV) (1,6,7). While these analyses have been essential for understanding the broader LRI landscape and guiding vaccination and child-survival strategies, they provide limited resolution on the distinct contribution of M. pneumoniae across diverse LMIC settings. Existing regional and national studies have often been constrained by limited surveillance coverage, hospital-based recruitment, or diagnostic approaches that remain dependent on test availability and interpretation, including serology-based strategies, thereby limiting comparability across age groups, settings, and time periods (8,9). Moreover, M. pneumoniae does not act in isolation: its burden in LMICs is likely amplified by household air pollution, malnutrition, human immunodeficiency virus (HIV) exposure, delayed care-seeking, and inequitable access to diagnostic and therapeutic services (10). In this sense, examining burden through the lens of socio-demographic development is not only epidemiologically relevant but also useful for understanding how the “inverse care law” continues to shape child respiratory outcomes in resource-limited settings (10,11). This study provides a systematic analysis of the fatal and non-fatal disease burden of LRIs attributable to Mycoplasma among individuals aged 0–19 years in LMICs from 1990 to 2023. Utilising data and standardised methodological frameworks from the Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2023, we estimated deaths and disability-adjusted life years (DALYs), and corresponding rates, and further evaluated temporal trends, inequality, decomposition, and frontier performance. By presenting estimates stratified by age, sex, region, and socio-demographic index (SDI), this analysis aims to fill a critical evidence gap, inform priority-setting for diagnostic and therapeutic resources, and support future child-health planning in resource-constrained settings. We present this article in accordance with the GATHER reporting checklist (available at https://tp.amegroups.com/article/view/10.21037/tp-2026-1-0134/rc). Methods Study overview This study presents GBD 2023 estimates for LRIs attributable to Mycoplasma among children and adolescents (aged 0–19 years) in LMICs from 1990 to 2023. An international network of collaborators provided, reviewed, and assessed the vast array of data used to generate GBD 2023 estimates (12). We extracted pathogen-specific burden estimates from the publicly available GBD 2023 Results Tool (https://vizhub.healthdata.org/gbd-results/) and used GBD population estimates as denominators for rate calculations. The analysis focused on deaths, DALYs, temporal trends, inequality, decomposition, and comparative benchmarking across 93 LMICs. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. GBD estimation framework and pathogen attribution This study adheres to the methodological framework of the GBD 2023, which has been extensively documented (12-14). GBD 2023 synthesises multiple data streams, including vital registration, sample registration, verbal autopsy, surveillance systems, hospital data, household surveys, censuses, and published studies. For locations and periods with sparse direct evidence—particularly in many LMICs during the early 1990s—GBD applies standardised data processing, redistribution of poorly specified causes, and predictive modelling to improve comparability across time and place. Cause-specific mortality for most causes is estimated using the Cause of Death Ensemble model (CODEm), which evaluates alternative model specifications according to out-of-sample predictive validity (12,13). In brief, the total burden of disease due to LRIs—encompassing both fatal and non-fatal outcomes—is modelled first. For mortality, CODEm and other Bayesian modelling tools were employed to synthesise data from vital registration systems, verbal autopsies, and surveillance systems to estimate the total number of LRI deaths. Years of life lost (YLLs) are calculated by multiplying the number of deaths at each age by a standard life expectancy at that age. For incidence, prevalence, and the resulting years lived with disability (YLDs), the total LRI burden is modelled initially. Within this framework, the proportion of the total LRI burden attributable to Mycoplasma is then estimated as an etiologic fraction (14). This fraction is derived from systematic reviews and meta-analyses of pathogen-specific aetiological studies. The included studies, comprising surveillance data and hospital-based case series, report the proportion of LRI cases (both fatal and non-fatal) that are confirmed or presumed to be caused by M. pneumoniae. This etiologic fraction varies by age, geographic region, and clinical setting, and is subsequently applied to the total LRI mortality, YLLs, and YLDs estimates to calculate pathogen-specific deaths, YLLs, and YLDs. DALYs attributable to M. pneumoniae were calculated as the sum of these pathogen-specific YLLs and YLDs. Age and geographical stratification Burden estimates were produced for the following detailed paediatric age groups: <1 year, 12–23 months, 2–4 years, 5–9 years, 10–14 years, and 15–19 years, and are presented for both sexes combined. For this analysis, LMICs were operationally defined as all countries and territories falling within the low, low-middle, and middle SDI quintiles. Results were aggregated and presented for three overarching SDI categories (low, low-middle, and middle SDI), as well as for the 10 constituent GBD regions that encompass these 93 countries and territories. Statistical analysis Temporal trends To characterise trends in mortality and DALY rates from 1990 to 2023, we assessed temporal changes using joinpoint regression on the natural logarithm of rates. Following the Joinpoint Regression Program framework, the analysis begins with the simplest log-linear model and identifies statistically significant inflection points only when additional joinpoints improve model fit. Statistical significance is evaluated using Monte Carlo permutation tests, and the average annual percentage change (AAPC) is reported as a summary measure of the overall direction and magnitude of change across the full study period (15). Rates rather than counts were analysed to account for demographic changes over time. Association between disease burden and SDI We assessed the cross-sectional relationship between the burden (death and DALY rates) and the SDI at the location level for the year 2023. SDI is a composite measure of income per capita, educational attainment, and total fertility rate. Pearson correlation coefficients were calculated to quantify the strength and direction of the linear association between disease burden metrics and SDI, both across all 93 LMICs and within specific GBD regions. Inequality analysis We systematically assessed inequality in disease burden across countries in relation to socio-economic development. Two core methods were employed: the slope index of inequality, used to measure absolute inequality by calculating the absolute difference in burden rates between country groups at different SDI levels; and the concentration index, used to measure relative inequality associated with SDI (16). A negative concentration index indicates that the burden is disproportionately concentrated among countries with lower SDI. Decomposition analysis To understand the drivers of changes in the absolute number of DALYs between 1990 and 2023, we conducted a standard decomposition analysis. The total change was partitioned into contributions from three factors: population growth, changes in population age structure, and changes in age-specific DALY rates (17). This analysis was performed for the three SDI groups and selected high-burden GBD regions to elucidate whether changes were primarily due to demographic shifts or changes in epidemiological risk. Frontier analysis We performed a frontier analysis to benchmark the observed disease burden (DALY rate) against the level of socio-demographic development (SDI) for each location in 2023. For each SDI level, the “frontier” was defined as the lowest observed burden rate among all locations at that SDI or higher. The “frontier gap” for each location was then calculated as the difference between its observed burden and the frontier burden at its SDI. This analysis identifies locations that are underperforming relative to their development peers and quantifies the potential for improvement if best-practice performance were achieved (18). Data sources, processing, and uncertainty calculation All data sources used to produce the GBD 2023 estimates referenced in this study are catalogued in the GBD 2023 Sources Tool. Uncertainty is propagated throughout every stage of the GBD estimation process, with 95% uncertainty intervals (UIs) derived from 250 draws from the posterior distribution of each estimate. The uncertainty for derived metrics was estimated via simulation using the 250 draws of the input burden estimates (12,13). All data analysis and visualisation were conducted using R (version 4.4.2). Results Overall burden In 2023, LRIs attributable to Mycoplasma imposed a substantial burden among children and adolescents aged 0–19 years in LMICs. At the overall LMIC level, both mortality and DALY rates varied markedly across SDI groups (Table 1). The low SDI group had the highest mortality rate (1.97 per 100,000) and DALY rate (171.77 per 100,000), followed by the low-middle SDI group (mortality rate: 1.13 per 100,000; DALY rate: 99.86 per 100,000) and the middle SDI group (mortality rate: 0.64 per 100,000; DALY rate: 55.84 per 100,000). Table 1Disease burden of lower respiratory infections attributable to Mycoplasma among children and adolescents in LMICs, by sex and regions, 1990–2023Location199020231990–2023 (AAPC)Deaths (95% UI)Death rate (95% UI)DALYs (95% UI)DALY rate (95% UI)Deaths (95% UI)Death rate (95% UI)DALYs (95% UI)DALY rate (95% UI)Death rate (95% CI)DALY rate (95% CI)SDI regions Low SDI20,872 (16,093, 25,980)4.74 (3.65, 5.90)1,836,195 (1,412,224, 2,289,121)416.83 (320.59, 519.65)16,717 (13,052, 20,751)1.97 (1.54, 2.45)1,456,059 (1,125,944, 1,815,349)171.77 (132.83, 214.16)−2.80 (−3.21, −2.40)−2.83 (−3.24, −2.42) Low-middle SDI11,052 (8,530, 13,853)3.08 (2.38, 3.86)977,545 (752,781, 1,227,147)272.61 (209.93, 342.22)5,164 (4,254, 6,273)1.13 (0.93, 1.38)455,516 (374,709, 554,833)99.86 (82.15, 121.64)−3.31 (−3.62, −3.00)−2.44 (−2.73, −2.16) Middle SDI7,617 (6,398, 8,798)2.59 (2.18, 2.99)672,846 (563,897, 778,411)228.79 (191.75, 264.69)2,138 (1,851, 2,495)0.64 (0.55, 0.74)187,137 (161,508, 219,135)55.84 (48.20, 65.39)−4.11 (−4.54, −3.68)−4.13 (−4.56, −3.70)GBD regions Caribbean223 (168, 287)1.47 (1.11, 1.90)19,768 (14,912, 25,464)130.73 (98.61, 168.39)131 (97, 173)0.84 (0.62, 1.11)11,551 (8,515, 15,258)74.17 (54.68, 97.98)−1.61 (−1.95, −1.28)−1.63 (−1.96, −1.29) Central Asia1,326 (1,211, 1,483)4.15 (3.79, 4.64)117,543 (107,270, 131,678)367.99 (335.83, 412.25)651 (592, 716)1.75 (1.60, 1.93)57,504 (52,311, 63,274)154.94 (140.95, 170.49)−2.48 (−2.84, −2.12)−2.28 (−2.64, −1.92) Central Latin America994 (911, 1,083)1.20 (1.10, 1.31)87,518 (80,002, 95,511)106.00 (96.90, 115.68)394 (352, 439)0.47 (0.42, 0.52)34,409 (30,678, 38,348)40.89 (36.45, 45.57)−3.01 (−3.43, −2.58)−3.39 (−4.09, −2.69) Central Sub-Saharan Africa1,656 (1,206, 2,064)5.30 (3.86, 6.61)145,224 (105,638, 181,096)464.96 (338.22, 579.81)1,744 (1,313, 2,318)2.20 (1.66, 2.92)150,599 (113,066, 199,822)190.01 (142.66, 252.12)−2.87 (−3.32, −2.42)−2.92 (−3.38, −2.46) Eastern Sub-Saharan Africa4,937 (3,622, 6,106)4.48 (3.29, 5.54)430,777 (314,800, 533,254)391.03 (285.76, 484.05)4,345 (3,564, 5,256)1.82 (1.49, 2.20)374,433 (304,474, 453,320)156.96 (127.63, 190.03)−2.92 (−3.38, −2.46)−2.96 (−3.42, −2.49) Oceania87 (64, 111)2.55 (1.88, 3.28)7,692 (5,639, 9,867)226.28 (165.88, 290.24)115 (82, 156)1.68 (1.20, 2.29)10,145 (7,183, 13,823)149.03 (105.52, 203.06)−1.31 (−1.48, −1.13)−1.31 (−1.49, −1.13) South Asia16,653 (13,458, 20,182)3.11 (2.52, 3.77)1,476,307 (1,193,531, 1,791,689)276.05 (223.18, 335.02)6,413 (5,157, 7,749)0.92 (0.74, 1.11)569,728 (458,517, 689,864)81.96 (65.96, 99.24)−3.05 (−3.35, −2.76)−3.04 (−3.34, −2.75) Southeast Asia4,444 (3,386, 5,680)2.01 (1.53, 2.57)391,889 (296,708, 503,455)177.56 (134.43, 228.10)1,387 (1,105, 1,738)0.61 (0.48, 0.76)121,091 (96,542, 152,521)52.99 (42.25, 66.75)−3.87 (−4.11, −3.62)−3.90 (−4.15, −3.65) Southern Sub-Saharan Africa512 (414, 630)1.92 (1.55, 2.37)44,960 (36,035, 55,399)168.95 (135.42, 208.18)600 (492, 719)1.81 (1.49, 2.17)52,687 (43,250, 63,398)159.19 (130.68, 191.55)−0.07 (−0.74, 0.59)−0.31 (−0.87, 0.26) Western Sub-Saharan Africa6,573 (4,578, 8,634)6.08 (4.24, 7.99)574,477 (399,153, 757,887)531.74 (369.46, 701.51)8,439 (5,983, 11,394)2.99 (2.12, 4.04)734,482 (517,704, 992,171)260.66 (183.73, 352.11)−2.31 (−2.65, −1.97)−2.33 (−2.67, −1.98)All rates are presented per 100,000 population. AAPC, average annual percentage change; CI, confidence interval; DALYs, disability‑adjusted life years; GBD, Global Burden of Disease; LMICs, low‑ and middle‑income countries; SDI, socio‑demographic index; UI, uncertain interval. Disease burden of lower respiratory infections attributable to Mycoplasma among children and adolescents in LMICs, by sex and regions, 1990–2023 All rates are presented per 100,000 population. AAPC, average annual percentage change; CI, confidence interval; DALYs, disability‑adjusted life years; GBD, Global Burden of Disease; LMICs, low‑ and middle‑income countries; SDI, socio‑demographic index; UI, uncertain interval. Regional and national disease burden Marked spatial heterogeneity in disease burden was observed across GBD regions in 2023 (Table 1). Western Sub-Saharan Africa had the highest mortality rate (2.99 per 100,000) and DALY rate (260.66 per 100,000), followed by Eastern Sub-Saharan Africa (mortality rate: 1.82 per 100,000; DALY rate: 156.96 per 100,000) and Central Sub-Saharan Africa (mortality rate: 2.20 per 100,000; DALY rate: 190.01 per 100,000). By contrast, the Caribbean (mortality rate: 0.84 per 100,000; DALY rate: 74.17 per 100,000) and Central Latin America (mortality rate: 0.47 per 100,000; DALY rate: 40.89 per 100,000) showed comparatively lower burden. National-level estimates further illustrated this distribution (Table S1 and Figure 1). In 2023, the largest absolute numbers of deaths and DALYs were observed in Nigeria (deaths: 4,469; DALYs: 389,439), the Democratic Republic of the Congo (deaths: 1,147; DALYs: 99,067), and Pakistan (deaths: 1,563; DALYs: 138,859). Geographical distribution of mortality and DALY rates of Mycoplasma-attributable lower respiratory infections among children and adolescents in low- and middle-income countries, 2023. (A) Death rate per 100,000 population. (B) DALY rate per 100,000 population. Colour gradients indicate burden levels from low (light) to high (dark). DALY, disability‑adjusted life year. Age and sex patterns The burden of Mycoplasma-attributable LRIs varied significantly by age, sex, and SDI level (Figure 2). Overall, both mortality and DALY burden were highest in infancy (<1 year) and declined sharply with increasing age. In low SDI regions, the burden was substantially higher in infancy than in older age groups and was generally higher among males than among females (e.g., infant male DALY rate: 1,558.37 per 100,000, female: 1,310.16 per 100,000). In low-middle SDI regions, infancy also represented the peak-burden period, although rates were slightly higher among females than among males in several age groups (e.g., age 5–9 years: female, 26.13 per 100,000; male, 22.31 per 100,000). In middle SDI regions, the burden likewise remained concentrated in younger age groups, and, except among children aged 2–4 years, DALY rates were higher among males than among females across all age groups (infant male DALY rate: 741.28 per 100,000, female: 621.63 per 100,000). Age and sex patterns of the disease burden of Mycoplasma-attributable lower respiratory infections by SDI group, 2023. (A,C,E) Death rates stratified by age and sex. (B,D,F) DALY rates stratified by age and sex. Bars represent burden rates for each age group; error bars denote 95% uncertainty intervals. DALYs, disability‑adjusted life years; SDI, socio‑demographic index; UI, uncertain interval. Temporal trends From 1990 to 2023, mortality and DALY rates declined across all SDI groups (Figure 3), with the steepest reductions observed in the middle SDI group (mortality AAPC: −4.11; DALY AAPC: −4.13). Joinpoint regression showed that the declining trend in LMICs was non-linear, with a noticeable slowdown or plateau around 2010–2016; in the low SDI group, the pace of improvement also decelerated after 2006. Southeast Asia showed the largest regional reduction in burden between 1990 and 2023 (mortality AAPC: −3.87; DALY AAPC: −3.90), whereas Southern Sub-Saharan Africa showed no statistically meaningful decline in mortality (AAPC: −0.07). At the national level, Equatorial Guinea (AAPC: −6.82), Maldives (AAPC: −7.64), and Mongolia (AAPC: −6.61) experienced the largest declines in mortality rates. Temporal trends and joinpoint analysis of the disease burden of Mycoplasma-attributable lower respiratory infections, 1990–2023. (A,B) Death and DALY rates in the low SDI group, (C,D) low-middle SDI group, and (E,F) middle SDI group. Joinpoints indicate years with significant changes in trend. APC, annual percentage change; DALY, disability‑adjusted life year; SDI, socio‑demographic index. Association between disease burden and SDI and inequality analysis A significant inverse association between SDI and disease burden was observed at both regional and national levels, indicating that lower socio-demographic development was associated with a higher burden of disease (Figure 4). Inequality analysis further quantified this socio-economic gradient. In 2023, the slope index of inequality indicated an absolute difference of −2.21 per 100,000 for mortality rates and −191.86 per 100,000 for DALY rates between populations at the lowest and highest ends of the SDI ranking. The concentration index was negative, indicating a pro-poor distribution of burden, with disease burden disproportionately concentrated in lower-SDI countries (Figure 5A-5D). Correlation between disease burden of Mycoplasma-attributable lower respiratory infections and the SDI. CI, confidence interval; DALY, disability‑adjusted life year; SDI, socio‑demographic index. Inequality, decomposition, and frontier analyses of the disease burden of Mycoplasma-attributable lower respiratory infections. (A,B) Association between death rate and SDI with inequality indices. (C,D) Association between DALY rate and SDI with inequality indices. (E) Decomposition of changes in DALYs from 1990 to 2023 into contributions from population growth, ageing, and epidemiological change. (F) Frontier analysis of DALY rates against SDI in 2023, showing the gap between observed burden and the theoretical best achievable burden for each country. CI, concent ration index; DALYs, disability-adjusted life years; SDI, socio-demographic index; SII, slope index of inequality. Decomposition analysis Decomposition analysis quantified the drivers of change in DALYs between 1990 and 2023 across regions (Figure 5E). In low SDI regions, the absolute DALY burden increased by approximately 53,131 over the study period. Population growth contributed +110,933 DALYs (208.79%), and changes in population age structure contributed approximately +60,144 DALYs (113.20%), whereas epidemiological improvement, reflected by declining age-specific DALY rates, offset −117,946 DALYs (−221.99%). These findings indicate that demographic expansion more than offset gains from reductions in age-specific risk. In middle SDI regions, by contrast, declining age-specific DALY rates remained the dominant driver of overall burden reduction, contributing 124.05% and offsetting the effect of population growth (−61.19%). At the regional level, burden reduction in Southeast Asia and South Asia was likewise driven primarily by epidemiological improvement, with contribution rates of 110.63% and 138.33%, respectively. Frontier analysis Frontier analysis highlighted marked variation in health-system efficiency across countries at comparable SDI levels (Figure 5F). The largest frontier gaps were observed predominantly in Sub-Saharan Africa. Niger exhibited the greatest gap (359.91), with an observed DALY rate of 547.37 per 100,000 compared with a frontier value of 187.46 per 100,000 at an SDI of 0.20. Sierra Leone (312.34), Nigeria (264.39), and Eswatini (254.58) also showed substantial room for improvement. By contrast, Somalia (3.13) and the Solomon Islands (3.87) performed close to the theoretical frontier for their respective SDI levels, suggesting relatively efficient performance despite constrained resources. Notably, some middle-SDI countries, such as Uzbekistan, also showed sizeable frontier gaps, indicating that socio-demographic development alone does not fully explain cross-country differences in performance. Discussion This study provides the first comprehensive, GBD-based assessment quantifying the specific burden of LRIs attributable to M. pneumoniae among children and adolescents (0–19 years) across LMICs from 1990 to 2023. Our analysis reveals a significant and persistently inequitable burden patterned by socio-demographic development, geography, age, and sex. These findings move beyond aggregate LRI estimates to highlight a pathogen that requires distinct diagnostic and therapeutic approaches in resource-constrained settings. The profound socio-economic gradient observed is the most salient finding. The burden in low-SDI countries was approximately three to four times higher than in middle-SDI countries in 2023. This disparity starkly visualises the “inverse care law” in global health. The high concentration of burden in Sub-Saharan Africa, particularly Western and Central regions, aligns with broader patterns of inadequate healthcare infrastructure, poverty, and a high prevalence of risk factors for severe pneumonia (19,20). Our estimates translate these structural disadvantages into a substantial population-level burden of death and disability. The detailed age-stratified analysis challenges the conventional view of M. pneumoniae as primarily a pathogen of school-aged children and adolescents. We found the absolute risk of severe outcomes (death and DALYs) to be highest in infancy (<1 year), especially in low-SDI settings. This pattern likely reflects a confluence of factors, including close household exposure, the waning of maternally derived protection, neonatal and infant immune immaturity, poor nutritional status, and a greater likelihood of clinically important co-infections with other respiratory pathogens (10,21). The PERCH multi-country case-control study found that M. pneumoniae was detected in severe paediatric pneumonia in African and Asian sites, often as a co-pathogen (21). Taken together, these findings suggest that M. pneumoniae should not be regarded solely as a pathogen of older children when evaluating severe pneumonia risk in high-mortality LMIC settings. The sex-disaggregated burden patterns reveal a complex interplay of biological and social factors that vary across development contexts. In low and middle SDI settings, the male burden was generally higher, particularly pronounced in infancy, which is consistent with evidence that male infants have a higher innate risk for severe respiratory infections because of differences in immune maturation and airway development (22,23). However, the pattern in low-middle SDI regions, where female DALY rates surpassed male rates in the 5–9 and 10–14 years age groups, suggests an influential socio-behavioural dimension. This shift may reflect gender disparities in healthcare access, differences in care-seeking, or environmental exposure patterns (24,25). These nuanced sex patterns indicate that gendered determinants of health warrant more context-specific investigation in future LMIC studies. Our temporal trend analysis offers nuanced insights beyond a simple linear decline. Although all SDI groups showed significant reductions from 1990 to 2023, the trajectories were nonlinear and divergent. The most rapid declines occurred in middle-SDI regions, likely driven by broad improvements in living standards, healthcare access, and routine childhood vaccination systems (26). However, the deceleration or plateau in several LMIC settings after 2010 deserves careful interpretation. Because M. pneumoniae epidemics show periodicity and because circulation was markedly suppressed during the coronavirus disease 2019 (COVID-19) pandemic, the 2023 endpoint should not be misinterpreted as representing a stable post-pandemic equilibrium. Recent surveillance and modelling studies indicate that many countries entered a phase of global re-emergence after the lifting of pandemic restrictions, with renewed transmission in 2023–2025 and increased detection in younger age groups (27-29). The decomposition analysis suggests that the persistence of Mycoplasma-attributable LRI burden in low-SDI settings reflects not only residual epidemiological risk, but also broader demographic and health-system pressures. Recent GBD 2023 estimates indicate that LRI burden remains concentrated in young children and continues to disproportionately affect the most vulnerable regions, despite overall improvements in age-specific outcomes (14). Recent commentary on global pneumonia control has similarly emphasised that the heaviest burden still falls on the poorest settings, where timely access to effective care remains inadequate (30). This interpretation is further supported by contemporary evidence showing that inequitable access to essential respiratory care, including medical oxygen systems, remains a major constraint in low-resource settings (31). Against this background, reductions in age-specific burden may not translate into equally visible declines in total burden when population growth continues to increase the number of children at risk. Recent implementation evidence from primary-care settings also suggests that improving access to timely outpatient pneumonia management can strengthen effective care delivery while reducing costs for both families and health systems (32). Taken together, these findings indicate that pathogen-specific control strategies for M. pneumoniae should be embedded within broader child-survival and health-equity programmes if meaningful reductions in total burden are to be achieved in the poorest settings. Frontier analysis adds an important health-systems perspective. Countries such as Niger, Sierra Leone, Nigeria, and Eswatini showed large efficiency gaps relative to the best observed performance at similar SDI levels, whereas Somalia and Solomon Islands performed close to the theoretical frontier. Integrated Management of Childhood Illness (IMCI)-aligned triage, referral, and community-based case management have been shown to improve the delivery of childhood pneumonia care in resource-constrained contexts (33,34). In such settings, stronger first-contact access to care and earlier initiation of appropriate treatment are also plausible contributors to near-frontier performance (34). These findings suggest that the frontier gap should be interpreted not only as a marker of underdevelopment, but also as an indicator of unrealised health-system performance. The study also has implications for antimicrobial policy. Macrolides remain the mainstay of treatment for paediatric atypical pneumonia, yet rising concern about macrolide-resistant M. pneumoniae (MRMP) has become increasingly difficult to ignore. Recent post-pandemic surveillance and modelling studies have highlighted the renewed epidemic activity of M. pneumoniae in children and adolescents (27-29). At the same time, emerging evidence continues to underscore the clinical importance of MRMP and the need to better integrate resistance surveillance into interpretation of disease trends (35,36). Although our analysis was not designed to estimate the burden attributable to MRMP specifically, the slowing decline seen in some settings should be interpreted in the broader context of changing pathogen circulation, diagnostic practices, and resistance patterns. There are several limitations in this study. First, pathogen attribution relies on etiologic fractions derived from heterogeneous studies and may underrepresent community-acquired infections in settings with limited molecular testing. Second, the GBD framework models single-pathogen attribution and cannot fully capture co-infections or pathogen–pathogen interactions that may alter clinical severity and attribution. Third, our analysis ends in 2023 because this was the latest finalised public GBD release available at the time of analysis; consequently, the estimates do not capture the full post-pandemic resurgence of M. pneumoniae observed in 2024–2025 after several years of suppressed circulation during COVID-19-related non-pharmaceutical interventions (27-29). Fourth, MRMP was not explicitly incorporated into the present model. Future disease-burden assessments should account for the impact of antimicrobial resistance on incidence, treatment failure, mortality, duration of illness, and medical costs to provide a more comprehensive basis for policy and resource planning (37). Conclusions In conclusion, this study establishes M. pneumoniae as a significant and inequitably distributed contributor to the burden of LRIs among children and adolescents in LMICs. The burden demonstrates a steep socio-economic gradient, is concentrated in early childhood—particularly infancy—and exhibits context-dependent variation by sex. Although mortality and DALY rates declined from 1990 to 2023, progress has been uneven and has slowed in several vulnerable settings. In the poorest regions, demographic growth continues to outpace epidemiological gains, masking improvement at the population level. Future control strategies should combine earlier diagnosis, stronger community-to-facility case-management pathways, regionally adapted antimicrobial stewardship, and continued surveillance of post-pandemic resurgence and resistance patterns. Supplementary The article’s supplementary files as Acknowledgments We appreciate the high-quality data provided by the Global Burden of Disease Study 2023 collaborators. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Footnotes Reporting Checklist: The authors have completed the GATHER reporting checklist. Available at https://tp.amegroups.com/article/view/10.21037/tp-2026-1-0134/rc Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-2026-1-0134/coif). The authors have no conflicts of interest to declare. References Available at https://tp.amegroups.com/article/view/10.21037/tp-2026-1-0134/prf Supplementary Materials The article’s supplementary files as